Quince Therapeutics Reports Q1 2025 Results and Strategic Updates

Quince Therapeutics ( (QNCX) ) has released its Q1 earnings. Here is a breakdown of the information Quince Therapeutics presented to its investors.

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on leveraging patient biology to develop treatments for rare diseases. The company recently provided a business update and reported its financial results for the first quarter of 2025, highlighting strategic decisions and financial metrics.

Quince Therapeutics announced plans to potentially conclude enrollment early for its Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) by the end of June 2025. This decision aligns with the company’s existing cash runway, aiming to report topline results by early 2026. The trial has enrolled 63 participants so far, with all 19 study sites activated, including new sites in the U.K. and Europe.

Financially, Quince reported cash and short-term investments of $31.6 million as of March 31, 2025, with research and development expenses amounting to $8.1 million for the quarter. General and administrative expenses were $4.8 million, contributing to a net loss of $15.0 million, or $0.34 per share. The company anticipates its current cash reserves will support operations through the reporting of NEAT trial results.

Looking ahead, Quince Therapeutics remains focused on its strategic development path, with plans to submit regulatory applications in the U.S. and Europe in the second half of 2026, contingent on positive trial outcomes. The company is poised to continue its efforts in advancing treatments for rare diseases while maintaining financial prudence.